Loading...
XSWX
BION
Market cap3.35bUSD
Oct 21, Last price  
50.40CHF
1D
0.40%
1Q
1.00%
Jan 2017
-8.53%
IPO
181.88%
Name

BB Biotech AG

Chart & performance

D1W1MN
XSWX:BION chart
P/E
4.81
P/B
0.86
EPS
10.48
Vol. 1Y
25.67%
Shs. 5Y
-0.20%
Rev. 5Y
-35.71%
Div Yld LY
3.59%
Div Yld TTM
4.48%
Revenues
77m
-31.19%
318,065,0001,259,00070,436,00054,293,000-141,538,000-58,348,000376,820,000937,893,0001,476,387,000659,227,000-796,446,000693,053,000-465,753,000685,238,000699,233,000-396,220,0004,00035,000111,632,00076,812,000
Net income
578m
+661.71%
297,395,000-265,411,00045,353,00036,626,000-146,348,000-65,138,000367,834,000931,834,0001,470,139,000652,816,000-802,065,000687,503,000-471,343,000677,431,000691,174,000-404,808,000-357,812,000-206,607,00075,899,000578,133,000
CFO
309m
+1.51%
-19,804,000201,017,000509,390,000167,838,000-23,411,000169,521,000367,834,000931,834,0001,470,139,000652,816,000-802,065,000687,503,000-471,343,000215,021,000262,449,000-94,787,000-357,812,000218,276,000304,560,000309,145,000
Dividend
Mar 23, 20262.25 CHF/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

BB Biotech AG functions as an equity investment vehicle, managed by Bellevue Asset Management AG. Its investment mandate extends to publicly traded companies across the globe, with a particular focus on firms engaged in modern biotechnology for medications and diagnostic tools. The construction of its portfolio is driven by a rigorous fundamental analysis. This Swiss-domiciled entity was established on November 9, 1993.

Related entities

Subsidiaries (4)
Biotech Focus N.V.
Biotech Growth N.V.
Biotech Invest N.V.
Biotech Target N.V.

Key people

Clive Meanwell
Independent Vice Chairman of the Board · since 2022
Anna Aguado
Member Investment Management Team · since 2024
Maurizio Bernasconi
Deputy Head of the Investment Management Team · since 2023
Can Buldun-Gora
Member of the Investment Management Team - Data Scientist · since 2022
Samuel Croset
Member of the Investment Management Team - Data Scientist · since 2020
Leonidas Georgiou
Member of the Investment Management Team · since 2022
Christian Koch
Head of the Investment Management Team · since 2025
Wendy Lam
Member Investment Management Team - Deputy Head and Head of US Research · since 2024
Olivia Woolley
Member of the Investment Management Team - Data Scientist · since 2022
Laura Hamill
Independent Director · since 2022
Pearl Huang
Independent Director · since 2022
Camilla Soenderby
Independent Director · since 2024
Mads Thomsen
Independent Director · since 2022
Thomas Von Planta
Independent Chairman of the Board · since 2024
URL
https://www.bbbiotech.ch/
IPO date
Nov 08, 2006
Employees
10
Domiciled in
CH
Incorporated in
CH
Headquarters & legal address
Schwertstrasse 6
Schaffhausen, SH 8200
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT